Table 2 Preliminary pharmacokinetic (PK) evaluation of compound BE-33 in C57BL/6 micea.

From: SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target

Dose

Route

T1/2 (h)

Tmax (h)

Cmax (ng/mL)

AUClast (h*ng/mL)

AUCINF_obs (h*ng/mL)

CL (mL/min/kg)

MRTINF_obs (h)

Vss_obs (mL/kg)

F (%)

10 mg/kg

po

4.45 ± 0.67

0.25 ± 0.00

497 ± 80

2699 ± 791

2776 ± 806

–

6.67 ± 0.47

–

51

2.5 mg/kg

iv

5.67 ± 1.09

–

–

1324 ± 330

1405 ± 393

31.10 ± 7.90

7.53 ± 1.90

13535 ± 1699

–

  1. T1/2 half-life, Tmax time to maximum plasma concentration, Cmax maximum plasma concentration, AUClast area under curve measured until the last data point, AUCINF_obs area under curve from dosing time extrapolated to infinity based on the last observed concentration, CL clearance, MRTINF_obs mean residence time from dosing time extrapolated to infinity, based on the last observed concentration, Vss_obs steady-state volume of distribution based on the last observed concentration, F fraction absorbed (bioavailability).
  2. an = 3 in each dose group.
Back to article page